Lower-dose radiation effective, safe for HPV+ head and neck cancer after induction chemo

February 13, 2018, American Society for Radiation Oncology

Results of the phase II OPTIMA clinical trial indicate that patients with head and neck cancers associated with the human papillomavirus (HPV), including those with advanced nodal disease, can receive substantially lower radiation doses safely and effectively if they respond to induction chemotherapy initially. Patients who responded well to induction chemotherapy and subsequently received the lower-dose treatment experienced excellent survival—92 percent were without evidence of recurrence two years after treatment—and had improved functional outcomes with fewer side effects, compared to those who received standard chemoradiation therapy. The study will be presented today in an online news briefing and at the 2018 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale, Arizona.

Compared with HPV?negative head and neck cancer, which typically is caused by smoking and alcohol consumption, HPV-positive disease is more responsive to radiation and chemotherapy and is associated with significantly higher cure rates.

"Head and neck tumors that are caused by HPV respond well to therapy and can be cured reliably," said Tanguy Seiwert, MD, lead author of the study and an assistant professor of medicine at University of Chicago Medicine. "In fact, the effectiveness of combined treatment with radiation and chemotherapy has been so well documented that newer studies such as OPTIMA are focused on selecting who can safely receive less treatment."

Although reducing the intensity of cancer treatment offers patients potentially better quality of life, clinicians are careful to use this approach only for patients with a favorable biology for lower-dose therapy. The OPTIMA trial examined response to induction chemotherapy—which is systemic therapy given prior to radiation therapy—as a method to select patients likely to benefit from reduced treatment.

"With our approach of using induction chemotherapy to identify candidates for de-escalated radiation therapy, we achieved excellent treatment outcomes with giving 30 to 35 percent smaller , even for patients with advanced nodal stages such as N2C. Patients experienced less toxicity and survival rates exceeded historic data, although more follow-up is needed to confirm these findings," said Dr. Seiwert.

"This degree of de-escalation with high-risk patients is novel, as is selection using induction as the key component to reduce radiation doses and subsequent toxicities to such low levels. In my opinion, treatment for HPV-positive disease should be de-escalated when possible, and induction is an ideal method to identify HPV-related head and neck cancer biology."

Sixty-two patients with HPV-related head and neck cancers were enrolled in OPTIMA. Patients were classified as either low-risk (?T3, ?N2B, ?10 pack-year smoking history) (45% of patients) or high-risk (T4 or ?N2C or >10 pack-years) (55%). The median patient age was 57 years (range 31-85 years), and most patients (85%) were male.

All patients in the trial received three cycles of induction chemotherapy consisting of carboplatin and nab-paclitaxel, and those who responded well received one of two de-escalated treatment regimens: 50 Gray (Gy) of alone (RT50 arm) for low-risk disease, or 45Gy of chemoradiation therapy (CRT45 arm) for high-risk disease. Favorable response to was defined as 50 percent or greater reduction in tumor size for high-risk patents and 30 percent or greater reduction for low-risk patients. Patients without a favorable response received regular-dose chemoradiation therapy to 75 Gy. Radiation therapy was delivered over five weeks of 2 Gy daily fractions on the RT50 arm. On the CRT45 and CRT75 arms, treatment consisted of paclitaxel, 5-fluorouracil and hydroxyurea systemic therapy with 1.5 Gy twice-daily every other week. Median follow-up for the study was 22.3 months (range 9-39 months).

All low-risk patients and 32 of the 34 (94%) of the high-risk patients were progression-free at two years following treatment. Two-year overall survival rates were 100 percent for low-risk patients and 97 percent for high-risk patients. One high-risk patient on the CRT45 arm experienced a local recurrence at 11 months following treatment, but the recurrence was treated with salvage surgery.

Side effects from de-escalated therapy were significantly improved compared to standard . Rates of grade 3 or higher mucositis were 16 percent for RT50, 46 percent for CRT45 and 60 percent for CRT75 (p = 0.033). No RT50 patients experienced grade three or higher dermatitis, and the rates were 21 percent for CRT45 and 30 percent for CRT75 (p = 0.056). No RT50 patients experienced long-term dependency on a feeding tube, and the rates were 3.5 percent for CRT45 and 9 percent for CRT75 (p < 0.0001).

Explore further: Nivolumab immunotherapy safe, feasible during chemoradiation for adv. head and neck cancer

More information: The abstract, "OPTIMA—A Phase II Trial of Induction Chemotherapy Response-Stratified RT Dose and Volume De-escalation for HPV+ Oropharynx Cancer: Efficacy, Toxicity, and HPV Subtype Analysis," will be presented in detail during the Plenary Session at the 2018 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale, Arizona.

Related Stories

Nivolumab immunotherapy safe, feasible during chemoradiation for adv. head and neck cancer

February 13, 2018
Analysis of a clinical trial, RTOG Foundation 3504, finds that nivolumab immunotherapy can be administered safely in conjunction with radiation therapy and chemotherapy for patients with newly diagnosed local-regionally advanced ...

Halving radiation therapy for HPV-related throat cancer offers fewer side effects, similar outcomes

September 25, 2017
Mayo Clinic researchers have found that a 50 percent reduction in the intensity and dose of radiation therapy for patients with HPV-related throat cancer reduced side effects with no loss in survival and no decrease in cure ...

The best treatment for laryngeal cancer? This approach helps decide

February 2, 2017
Even as treatment options for laryngeal cancer seemed to improve, survival rates did not. For the most advanced patients, 50 percent survival was the norm, whether patients had surgery to totally remove the voice box or alternative ...

Radiation plus chemotherapy provides long-term positive results for head and neck cancer patients

January 26, 2012
A select subgroup of advanced head and neck cancer patients treated with radiation therapy plus the chemotherapy drug cisplatin had more positive outcomes than patients treated with radiation therapy alone and continued to ...

Chemotherapy before chemoradiation shows no survival advantage in head and neck cancer

February 18, 2016
Head and neck cancer patients who receive chemotherapy prior to radiation therapy (induction chemotherapy or IC) rather than the standard treatment that combines chemotherapy with radiation (chemoradiation or CRT) show no ...

Proton therapy may be better option for elderly patients with esophageal cancer

October 25, 2017
A study led by Mayo Clinic researchers has found that proton beam therapy, in combination with chemotherapy, prior to surgery, may be a better option than a combination using traditional radiation therapy techniques with ...

Recommended for you

New 'SLICE' tool can massively expand immune system's cancer-fighting repertoire

November 15, 2018
Immunotherapy can cure some cancers that until fairly recently were considered fatal. In addition to developing drugs that boost the immune system's cancer-fighting abilities, scientists are becoming expert at manipulating ...

Anti-malaria drugs have shown promise in treating cancer, and now researchers know why

November 15, 2018
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson ...

Researchers identify a mechanism that fuels cancer cells' growth

November 14, 2018
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified sodium glucose transporter 2, or SGLT2, as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes ...

A new approach to detecting cancer earlier from blood tests: study

November 14, 2018
Cancer scientists led by principal investigator Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have combined "liquid biopsy", epigenetic alterations and machine learning to develop a blood test to detect and classify ...

New antibody breakthrough to lead the fight against cancer

November 14, 2018
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defence against the body's immune system.

Photoacoustic imaging may help doctors detect ovarian tumors earlier

November 14, 2018
Ovarian cancer claims the lives of more than 14,000 in the U.S. each year, ranking fifth among cancer deaths in women. A multidisciplinary team at Washington University in St. Louis has found an innovative way to use sound ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.